Posted by Michael Wonder on 14 Mar 2024
ICER publishes final evidence report on treatments for paroxysmal nocturnal haemoglobinuria
13 March 2024 - Independent appraisal committee voted that current evidence is not adequate to demonstrate a net health benefit for iptacopan over C5 inhibitor; committee voted that the evidence is adequate to demonstrate a net health benefit for add-on danicopan compared to C5 inhibitor alone.
The ICER today released a final evidence report assessing the comparative clinical effectiveness and value of iptacopan (Novartis) and danicopan (Alexion Pharmaceuticals) for the treatment of paroxysmal nocturnal haemoglobinuria.
